Infectious Disease Molecular Diagnostics Market Size & Growth Forecast 2027–2036, By Segments (Product, Application, End Use, Technology), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Infectious Disease Molecular Diagnostics Market size was assessed at USD 17.9 billion in 2026 and is poised to grow at a 3.23% CAGR between 2027 and 2036, crossing USD 24.6 billion by 2036. The industry revenue for 2027 is estimated at USD 18.39 billion.
Get more details on this report
Request Free Sample ReportInfectious Disease Molecular Diagnostics Market Intelligence Snapshot
Regional Market Dynamics
- North America leads with 43.35% share, supported by widespread PCR/NAAT testing, strong reimbursement systems, and high laboratory automation across healthcare networks.
- Asia Pacific is growing at 4.67% CAGR due to expanding lab infrastructure, rising testing demand, and a shift toward scalable molecular diagnostic workflows in urban centers.
Segment Momentum
- Respiratory Diseases accounted for 69.08% of the market in 2026 because frequent testing demands require rapid and accurate molecular diagnosis to support timely treatment decisions and infection control.
- HPV is the fastest-growing application because molecular diagnostics provide precise early-stage viral detection, making them well suited for screening workflows and expanding clinical adoption.
Market Expansion Drivers
- Rising global infectious disease burden increasing demand for rapid molecular diagnostic testing.
- Advancements in PCR and next-generation sequencing improving pathogen detection accuracy and turnaround time.
- Expanding government funding and point-of-care innovation accelerating molecular diagnostics accessibility.
Leading Market Participants
- Top companies in the infectious disease molecular diagnostics market include F. Hoffmann-La Roche Ltd (Switzerland), Abbott Laboratories (United States), Danaher Corporation (United States), bioMérieux SA (France), Siemens Healthineers AG (Germany), Hologic, Inc. (United States), QIAGEN N.V. (Netherlands), Bio-Rad Laboratories, Inc. (United States), Becton, Dickinson and Company (United States), Sysmex Corporation (Japan).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 17.9 billion
- 2027 Estimated Market Size: USD 18.39 billion.
- Projected Market Size: USD 24.6 billion by 2036
- Growth Forecast: 3.23% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Reagents (Product) | Respiratory Diseases (Application) | Diagnostics Laboratories (End Use) | Polymerase Chain Reaction (PCR) (Technology)
- Emerging Opportunity Segment: Reagents (Product) | HPV (Application) | Research Institutes (End Use) | In Situ Hybridization (Technology)
Market Growth Drivers and Industry Trends
Rising global infectious disease burden increasing demand for rapid molecular diagnostic testing
The infectious disease molecular diagnostics market is benefiting from the persistent burden of infectious diseases, which increases the need for rapid and reliable pathogen identification. Molecular tests can detect genetic material associated with infectious agents and help healthcare providers identify infections more efficiently than approaches that depend solely on conventional laboratory methods. Faster diagnostic information supports timely clinical decisions, infection management, and appropriate treatment selection across healthcare settings.
Advancements in PCR and next-generation sequencing improving pathogen detection accuracy and turnaround time
Advancements in PCR and next-generation sequencing are propelling the infectious disease molecular diagnostics market by improving the sensitivity, specificity, and breadth of pathogen detection. Modern molecular technologies can identify infectious agents from clinical samples with greater analytical precision while supporting the detection of multiple targets and emerging pathogens. Faster workflows and improved analytical capabilities are also helping laboratories obtain actionable diagnostic information more efficiently.
Expanding government funding and point-of-care innovation accelerating molecular diagnostics accessibility
Government funding and continued innovation in point-of-care testing are expanding the infectious disease molecular diagnostics market by improving access to advanced diagnostic capabilities across healthcare environments. Public investment can support laboratory infrastructure, disease surveillance, testing programs, and deployment of modern diagnostic technologies, while portable molecular systems can bring testing closer to patients. Greater availability of rapid testing outside centralized laboratories can facilitate earlier identification and management of infectious diseases.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising global infectious disease burden increasing demand for rapid molecular diagnostic testing | 2.00% | High | North America, Asia Pacific | High | Near Term |
| Advancements in PCR and next-generation sequencing improving pathogen detection accuracy and turnaround time | 1.80% | High | North America, Europe | High | Mid Term |
| Expanding government funding and point-of-care innovation accelerating molecular diagnostics accessibility | 1.50% | High | Asia Pacific, Latin America | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
In the infectious disease molecular diagnostics market, North America held the largest share of 43.35% in 2026. The region's leadership reflects advanced laboratory infrastructure, strong demand for rapid and accurate pathogen identification, and widespread integration of molecular testing into clinical diagnostics. Healthcare providers increasingly rely on molecular techniques to support timely treatment decisions and infection management, while public health systems maintain substantial capabilities for disease surveillance and outbreak response. Continued technological advancement in nucleic acid testing, automation, and multiplex diagnostic approaches is further strengthening adoption. Established regulatory frameworks and high clinical awareness of molecular diagnostic methods also provide a supportive environment for market development.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is experiencing the fastest growth, supported by expanding diagnostic capacity, rising healthcare investment, and increasing attention to infectious disease surveillance. Improvements in laboratory infrastructure are enabling healthcare facilities to adopt more advanced testing technologies, while growing awareness of the importance of early and accurate diagnosis is increasing demand for molecular approaches. The region's diverse infectious disease burden also creates a strong need for sensitive diagnostic tools that can support clinical management and public health programs. Increasing healthcare modernization and broader availability of automated and decentralized testing technologies are expected to further encourage adoption across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Laboratory Automation FocusGermany prioritizes molecular diagnostic systems that enhance laboratory efficiency, testing accuracy, and regulatory compliance. Suppliers are introducing automated workflows and high-throughput platforms to support healthcare providers managing diverse infectious disease testing requirements.
France 🇫🇷
Public Health DiagnosticsFrance focuses on molecular diagnostic solutions that strengthen infectious disease surveillance and improve coordination across healthcare institutions. Developers are enhancing assay portfolios and laboratory connectivity to support efficient testing and public health response initiatives.
Italy 🇮🇹
Hospital Testing EfficiencyItaly is increasing adoption of molecular diagnostic technologies that streamline infectious disease detection in hospitals and clinical laboratories. Suppliers are emphasizing automated sample processing and flexible testing platforms that improve operational efficiency and diagnostic consistency.
Japan 🇯🇵
Precision Diagnostic IntegrationJapan is advancing molecular diagnostics through highly accurate testing technologies that integrate with established clinical laboratory networks. Companies are refining compact, automated systems that deliver reliable results while supporting routine infectious disease screening and hospital workflows.
South Korea 🇰🇷
Advanced Diagnostic PlatformsSouth Korea continues to strengthen molecular diagnostics through innovation in PCR systems, digital diagnostics, and integrated laboratory technologies. Market participants are expanding rapid testing capabilities and scalable diagnostic platforms to improve preparedness for infectious disease monitoring.
United States 🇺🇸
Rapid Testing InnovationThe U.S. infectious disease molecular diagnostics market emphasizes rapid, multiplex testing platforms that improve clinical decision-making across hospitals and decentralized settings. Manufacturers are expanding automation, point-of-care compatibility, and laboratory integration to support timely diagnosis and efficient disease surveillance.
Segment Leadership and Growth Trends
Infectious Disease Molecular Diagnostics Market Share (%), by Product, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: Reagents (Largest & Fastest-Growing Segment)
The reagents segment led the infectious disease molecular diagnostics market in 2026 and also represents the fastest-growing product category, reflecting the essential role of reagents in enabling accurate molecular detection, amplification, and identification of infectious pathogens. Their recurring use across diagnostic workflows, combined with increasing demand for rapid and reliable testing, supports sustained adoption in clinical laboratories and diagnostic settings. Advances in assay sensitivity, specificity, multiplexing, and workflow compatibility are further strengthening the value of reagent-based solutions, while the growing emphasis on early disease detection and efficient laboratory testing continues to reinforce the segment's market position.
Application Segment Analysis: Respiratory Diseases (Largest Segment) vs HPV (Fastest-Growing Segment)
Respiratory diseases accounted for the largest share of the infectious disease molecular diagnostics market, representing 69.08% in 2026, supported by the persistent need for rapid identification of respiratory pathogens and the clinical importance of distinguishing infections with overlapping symptoms. Molecular diagnostic methods provide sensitive and specific detection capabilities, making them valuable for timely diagnosis and treatment decisions. Continued demand for reliable respiratory testing across healthcare settings, together with greater awareness of pathogen surveillance and infection control, has helped respiratory disease applications maintain their leading position.
HPV applications are advancing as the fastest-growing segment, driven by the expanding role of molecular testing in cervical cancer prevention and risk assessment. The ability to identify high-risk HPV infections before more serious disease develops supports earlier intervention and strengthens the clinical value of molecular diagnostics. Increasing emphasis on screening programs, improved access to preventive healthcare, and the adoption of sensitive nucleic-acid-based testing methods are creating favorable conditions for broader HPV diagnostic utilization.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Instruments, Reagents, Services | Reagents | Reagents |
| Application | Respiratory Diseases, Tuberculosis, Meningitis, Gastrointestinal Tract Infections, HPV, Sexually Transmitted Infections, Sepsis, Drug Resistance Diseases, Others | Respiratory Diseases | HPV |
| End Use | Hospitals, Clinics, Diagnostics Laboratories, Research Institutes | Diagnostics Laboratories | Research Institutes |
| Technology | Polymerase Chain Reaction (PCR), In Situ Hybridization, Isothermal Nucleic Acid Amplification Technology (INAAT), Chips and Microarrays, Mass Spectrometry, Transcription Mediated Amplification, Others | Polymerase Chain Reaction (PCR) | In Situ Hybridization |
Competitive Landscape and Market Positioning
Leading companies in the infectious disease molecular diagnostics market:
1. F. Hoffmann-La Roche Ltd (Switzerland)
2. Abbott Laboratories (United States)
3. Danaher Corporation (United States)
4. bioMérieux SA (France)
5. Siemens Healthineers AG (Germany)
6. Hologic Inc. (United States)
7. QIAGEN N.V. (Netherlands)
8. Bio-Rad Laboratories Inc. (United States)
9. Becton Dickinson and Company (United States)
10. Sysmex Corporation (Japan)
The infectious disease molecular diagnostics market is advancing through improved molecular detection technologies. Innovation is enhancing diagnostic speed and accuracy for emerging pathogens. Collaborative research efforts are strengthening global health response capabilities. Continuous development is supporting next-generation diagnostic solutions.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| F. Hoffmann-La Roche Ltd (Switzerland) | |||||||
| Abbott Laboratories (United States) | |||||||
| Danaher Corporation (United States) | |||||||
| bioMérieux SA (France) | |||||||
| Siemens Healthineers AG (Germany) | |||||||
| Hologic Inc. (United States) | |||||||
| QIAGEN N.V. (Netherlands) | |||||||
| Bio-Rad Laboratories Inc. (United States) | |||||||
| Becton Dickinson and Company (United States) | |||||||
| Sysmex Corporation (Japan). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Advanced Biological Laboratories | Feb-25 | ABL signed a license and know-how transfer agreement with Siemens Healthineers for the Fast Track Diagnostics (FTD) PCR portfolio. This acquisition enables ABL to integrate FTD’s syndromic testing capabilities into its own diagnostic suite, creating a comprehensive technological continuum from pathogen detection and identification to clinical interpretation. |
| IMMY | Jun-24 | IMMY acquired Newcastle-based OLM Diagnostics, a specialist in fungal diagnostic tests. The strategic transaction integrates OLM’s molecular diagnostic portfolio into IMMY’s operations, strengthening the company’s ability to provide laboratorians and clinicians with advanced tools for the precise identification of drug-resistant fungal infections. |
| bioMérieux | Jan-24 | bioMérieux completed the full acquisition of LUMED, a Canadian software company specializing in clinical decision support systems. By integrating LUMED’s antimicrobial stewardship modules into its BIOMÉRIEUX VISION SUITE, the company enhances its capability to help hospitals optimize prescription protocols and monitor healthcare-associated infections using actionable laboratory data. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Infectious Disease Molecular Diagnostics Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Sample Type | Blood and Plasma, Respiratory Samples, Urine, Stool and Other Gastrointestinal Samples, Cerebrospinal Fluid, Tissue and Swab Samples |
| Automation Level | Manual and Semi-Automated, Automated, Fully Automated Integrated Systems |
| Reimbursement Status | Fully Reimbursed Testing, Partially Reimbursed Testing, Non-Reimbursed or Self-Pay Testing |
Infectious Disease Molecular Diagnostics Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| Decentralized and Point-of-Care Molecular Testing Outlook |
|
| Public Health Surveillance and Pandemic Preparedness Opportunities |
|
| Emerging Pathogen Testing Opportunity Assessment |
|
Need a different cut of the data?
Request Custom ResearchHow much revenue does the infectious disease molecular diagnostics market generate?
What are the growth projections for the infectious disease molecular diagnostics industry?
How is the rising infectious disease burden influencing molecular diagnostics adoption?
Why are laboratories investing in advanced PCR and next-generation sequencing platforms?
Why are Respiratory Diseases the largest application segment in the infectious disease molecular diagnostics market?
Why is HPV the fastest-growing application in the infectious disease molecular diagnostics market?
Why does North America lead the molecular diagnostics market?
What is driving growth in Asia Pacific molecular diagnostics market?
What are the prominent companies operating in the infectious disease molecular diagnostics landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Why It Matters | Reference |
|---|---|---|
| World Health Organization (WHO) | Global health statistics, disease burden, healthcare policies | www.who.int |
| U.S. Food & Drug Administration (FDA) | Medical devices, pharmaceuticals, diagnostics, approvals | www.fda.gov |
| European Medicines Agency (EMA) | Pharmaceutical approvals and regulatory guidance in Europe | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | Disease surveillance, public health, epidemiology | www.cdc.gov |
| National Institutes of Health (NIH) | Biomedical research, clinical studies, funding | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | Biomedical databases, PubMed, genomics | www.ncbi.nlm.nih.gov |
| PubMed | Peer-reviewed biomedical literature | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | Global clinical trial registry | clinicaltrials.gov |
| International Organization for Standardization (ISO) | Medical device quality and healthcare standards | www.iso.org |
| ASTM International | Medical device testing and material standards | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | Medical devices and diagnostics industry | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | Medical device innovation and regulatory science | mdic.org |
| Biotechnology Innovation Organization (BIO) | Biotechnology industry developments | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Global pharmaceutical industry | www.ifpma.org |
| U.S. Pharmacopeia (USP) | Drug quality standards and reference materials | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | European pharmaceutical quality standards | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | Veterinary healthcare and animal diseases | www.woah.org |
| American Hospital Association (AHA) | Hospital operations and healthcare delivery | www.aha.org |
| OECD Health | International healthcare expenditure and system statistics | www.oecd.org/health |
| World Bank Data | Healthcare expenditure and demographic indicators | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization